+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID07917351

Evaluating AI-Assisted Digital Management to Improve Medication Safety and Reduce Healthcare Burden in Advanced Solid Tumors A Controlled Real-World Study

Led by Tianjin Medical University Second Hospital · Updated on 2026-11-04

420

Participants Needed

2

Research Sites

47 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a digital whole-course management model for patients with advanced solid tumors stage III-IV who are receiving chemotherapy, targeted therapy, immunotherapy, or endocrine therapy. This prospective, single-center, controlled real-world study aims to assess whether using a smartphone-based oncology management app can improve medication safety, reduce healthcare burden, and support treatment adherence in advanced cancer care. The study is sponsored by Tianjin Medical University Second Hospital and focuses on supportive care for these patients. Participants are divided into two groups one uses the digital management app featuring medication reminders, AI-assisted laboratory report interpretation with critical-value alerts to clinicians, adverse event self-reporting based on CTCAE 5.0, monthly online follow-up questionnaires, and a module for clinical trial participants. The conventional group receives routine outpatient follow-up and telephone contact without digital tools or real-time alerts. The study follows participants for 12 months, comparing adverse event rates, emergency visits, readmissions, dose reductions, treatment delays, missed doses, and time to adverse event recovery. During the study, participants complete monthly online questionnaires, report adverse events, and have laboratory reports interpreted with AI assistance digital group only. Researchers monitor medication adherence, adverse events, emergency department visits, readmissions, and treatment modifications over 12 months. The primary outcomes include incidence of any-grade and severe adverse events within 24 months of enrollment. This comprehensive monitoring aims to provide insights into the impact of digital tools on medication safety and healthcare burden in advanced cancer treatment.

CONDITIONS

Brief Title

AI-Assisted Whole-Course Management for Medication Safety and Healthcare Burden in Advanced Solid Tumors: A Prospective Controlled Study

Research Team

H

Haitao Wang, Ph.D

L

Lili Wang, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here